New! ADC Target Scoring Module
Streamline analysis for antibody-drug conjugate (ADC)-focused assays and perform quantitative continuous scoring and spatial analysis.
New! ADC Target Scoring Module Read More »
Press Releases
HALO AP 2.5 Advances Digital Pathology with Enhanced Automation, Collaboration, and Scalability
Albuquerque, NM, July 14, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced a new software release designed to streamline and scale digital pathology workflows through enhanced automation, collaboration, and system transparency.
Indica Labs Expands into Prostate Cancer, Improving NGS ConfidenceThrough Precise Tumor Quantification
Albuquerque, NM, June 30, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the launch of Prostate Macrodissect AI, a clinically validated algorithm designed to automate and quantify tumor content in FFPE prostate tissue specimens. Prostate Macrodissect AI is designed to operate in concert with Indica Labs’ broader HALO Clinical AI suite, enabling laboratories to build end-to-end AI-powered prostate cancer workflows from automated tumor detection and Gleason grading assistance through to optimized macrodissection and genomic test preparation within a single, validated digital pathology platform.
Indica Labs Unveils AI-Powered Companion Diagnostics Offering Ahead of ASCO 2026
Albuquerque, NM, May 27, 2026 – Indica Labs, the global leader in AI-powered digital pathology solutions, today announced a major expansion of its companion diagnostics (CDx) capabilities, positioning the company at the forefront of precision medicine innovation ahead of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
Indica Labs Unveils AI-Powered Companion Diagnostics Offering Ahead of ASCO 2026 Read More »
Industry Leaders Leica Biosystems, Indica Labs and Lunit Partner to Develop AI-Powered Computational Pathology Assays for PD-L1 and Emerging Biomarkers
VISTA, California, ALBUQUERQUE, New Mexico, and SEOUL, South Korea — May 26, 2026 — Leica Biosystems, a Danaher company and a global leader in end-to-end anatomic and digital pathology solutions, and Indica Labs, a global leader in AI-powered digital pathology software, today announced a strategic collaboration with Lunit (KRX:328130.KQ), a leading provider of AI solutions for cancer diagnostics and therapeutics, to develop AI-powered image analysis algorithms. The partnership will focus on PD-L1 and emerging immunohistochemistry (IHC) biomarkers, supporting scalable and consistent biomarker quantification through computational pathology tools. The first product is an AI-powered Lunit SCOPE algorithm designed for Leica Biosystems’ PD-L1 primary antibody (CAL10). The new algorithm, Lunit SCOPE PD-L1 CAL10 NSCLC1, is now available through Leica Biosystems’ Aperio AI Store.
Leica Biosystems and Indica Labs Expand Digital Pathology-Powered Diagnostics in the USA with Aperio HALO AP DX Software Launch
Vista, CA, and Albuquerque, NM, March 31, 2026 – Leica Biosystems, a Danaher company and a global leader in anatomic and digital pathology solutions, and Indica Labs, a global leader in artificial intelligence (AI)-powered digital pathology software, launches Aperio HALO AP DX image management system designed for use with the Aperio GT 450 DX scanner. Together, the Aperio HALO AP DX software and the Aperio GT 450 DX scanner provide a complete, integrated clinical digital pathology solution supporting on‑screen diagnostics across routine pathology workflows in the USA.
Indica Labs Surpasses 3,000 Deployments of HALO Digital Pathology Software Worldwide Since 2013
Albuquerque, NM, March 3, 2026 – Indica Labs, the global leader in AI-powered digital pathology software and services, today announces surpassing the 3,000th installation of HALO software worldwide.
HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories
Albuquerque, NM, February 12, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced recognition by KLAS for top customer-rated performance in the European digital pathology market.
HALO AP® is Now Rated in Best in KLAS®: Earning ‘A’ Grades in All Categories Read More »
Indica Labs Sets New Standard for Molecular Testing in Breast Cancer with Expansion of AI Macrodissection Portfolio
Albuquerque, NM, February 10, 2026 – Indica Labs, the world’s leading provider of AI-powered digital pathology solutions, today announced the expansion of its macrodissection portfolio with the launch of Breast Macrodissect AI . The suite now includes advanced algorithms for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and breast cancer, with prostate cancer planned for release in early 2026.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets
Albuquerque, NM, December 17, 2025 – Indica Labs, the global leader in AI-powered digital pathology, announced today that clinical revenue growth rate for HALO AP® is up 260% since 2023 and recurring revenue for 2025 shows a 200% increase year-over-year, reinforcing its position as a market leader in digital pathology diagnostics.
Indica Labs Reports 260% Clinical Revenue Growth and Expansion into New Global Markets Read More »